What are the key financial results for Abbott Laboratories for the quarter ending March 30, 1996?

The provided text is a directory listing and does not contain specific financial figures such as revenue, net income, or earnings per share. A thorough review of the full 10-Q document, specifically the financial statements and management's discussion and analysis, would be required to ascertain these details.

What business segments did Abbott Laboratories operate in during the first quarter of 1996?

The provided filing snippet does not detail Abbott's business segments. Investors would typically find this information in the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section of the full 10-Q filing, which would likely cover pharmaceuticals, medical devices, diagnostics, and nutritional products.

Are there any significant new developments or risks mentioned in this filing for Abbott Laboratories?

The provided text is limited to the filing's metadata and directory. To understand any new developments, strategic initiatives, or potential risks faced by Abbott Laboratories during this period, investors would need to consult the full 10-Q report, particularly the sections discussing business overview, risk factors, and legal proceedings.

How does this filing compare to Abbott's performance in previous quarters or the same quarter in the prior year?

The provided excerpt does not contain comparative financial data. To perform such an analysis, one would need to access the full 10-Q filing and compare the reported figures to prior periods' financial statements, which are usually included in the detailed filings or can be found in earlier SEC submissions.

ABT 10-Q Quarterly Report Q1 FY1996 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' 10-Q filing for the period ending March 30, 1996, indicates a company operating in the dynamic healthcare sector during the mid-1990s. While specific financial figures and operational details are not present in the provided text snippet, the filing signifies Abbott's commitment to regular disclosure with the SEC. Investors would typically look to such filings for updates on revenue, profitability, segment performance, and any significant corporate developments or risks. Given the period, investors would likely be interested in Abbott's performance relative to its peers, its strategic direction in areas like pharmaceuticals, diagnostics, and medical devices, and any impacts of regulatory changes or market trends. The absence of detailed financial data in this extract means a deeper dive into the full 10-Q document is necessary for a comprehensive assessment of the company's financial health and growth prospects at that time.

Key Highlights

1The filing is a 10-Q Quarterly Report for Abbott Laboratories (ABT).
2The report covers the period ending March 30, 1996.
3The filing date was May 14, 1996, indicating timely disclosure practices.
4The document is an official SEC filing, suggesting adherence to regulatory requirements.
5The presence of a directory listing implies the availability of detailed financial statements, management discussion, and other critical disclosures within the full filing.
6This report provides a snapshot of Abbott Laboratories' operations and financial status during the first quarter of 1996.
7Investors can use this filing to assess the company's performance and trends during that specific quarter.

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 1996

Summary

Key Highlights

Frequently Asked Questions